Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.91
-0.02 (-0.09%)
Streaming Delayed Price
Updated: 3:43 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...
Via
Benzinga
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
July 22, 2024
Neither is a leader right now, but one of them might be on track to change that.
Via
The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
July 20, 2024
The pharma's latest push to develop a weight loss pill isn't going well.
Via
The Motley Fool
Check Out What Whales Are Doing With PFE
July 19, 2024
Via
Benzinga
Decoding Pfizer's Options Activity: What's the Big Picture?
July 15, 2024
Via
Benzinga
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
July 18, 2024
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.
Via
Benzinga
Exposures
COVID-19
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
July 18, 2024
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
July 18, 2024
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025...
Via
Benzinga
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
July 18, 2024
Pfizer Inc (NYSE: PFE) is showing a bullish Golden Cross, indicating potential upward momentum for the stock.
Via
Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
July 18, 2024
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on Pfizer Inc.
Via
Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
July 18, 2024
These seven out-of-favor stocks across various sectors have the potential to stage a significant rebound as market conditions improve.
Via
InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.
Via
InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
July 18, 2024
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer.
Via
The Motley Fool
Current Analysis: Pfizer Inc.
July 17, 2024
Pfizer (PFE) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer’s share price rose about 20.5% from $36.32 to $30.02 as of...
Via
Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
Pfizer And Roche Advance On Their Weight Loss Drug Journeys
July 17, 2024
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On...
Via
Benzinga
3 Under $50 Stocks to Buy Now: Q3 Edition
July 17, 2024
For small do-it-yourself investors looking for value, the following under $50 stocks are worth buying in July 2024.
Via
InvestorPlace
Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
July 16, 2024
Medical Properties Trust's yield looks appealing, but it wouldn't have made up for the stock's 70% decline over the last three years.
Via
The Motley Fool
7 High-Yield Dividend Stocks Beating Inflation
July 16, 2024
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
July 15, 2024
Via
Benzinga
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
July 13, 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector.
Via
InvestorPlace
2 Pharma Stocks to Buy Hand Over Fist This Month
July 13, 2024
These drugmakers may not be in perfect health right now, but that shouldn't last much longer.
Via
The Motley Fool
Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
July 12, 2024
Inflation drops, speculations rise on interest rate cuts. Producer inflation data fails to alter expectations, tech sector underperforms.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
July 12, 2024
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Via
Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
July 12, 2024
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate...
Via
Benzinga
Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
July 12, 2024
Pfizer selected Danuglipron, its once-daily weight loss drug, for continued advancement based on an ongoing pharmacokinetic study.
Via
Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
July 11, 2024
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.